N-(2-Aminoethyl)-pentan-1,5-diamin | 35513-88-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-Aminoethyl)-pentan-1,5-diamin
• 英文别名: N'-(2-aminoethyl)pentane-1,5-diamine
• CAS: 35513-88-3
• 化学式: C₇H₁₉N₃
• mdl: MFCD19206554
• 分子量: 145.248
• InChiKey: BSPZUPKVZVBJEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  64.1
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  乙烯亚胺 、 1,5-二氨基戊烷 在 氯化铵 作用下， 生成 N-(2-Aminoethyl)-pentan-1,5-diamin
  参考文献：
  名称：

  α，ω-亚烷基二胺的氨乙基衍生物的合成及其与多胺-牛血浆胺氧化酶系统的构效关系。

  摘要：

  DOI：

  10.1021/jm00293a005

文献信息

• USE OF NITROGEN COMPOUNDS QUATERNISED WITH ALKYLENE OXIDE AND HYDROCARBYL-SUBSTITUTED POLYCARBOXYLIC ACID AS ADDITIVES IN FUELS AND LUBRICANTS
  申请人：BASF SE

  公开号：US20160130514A1

  公开（公告）日：2016-05-12

  The invention relates to the use of quaternized nitrogen compounds as a fuel and lubricant additive or kerosene additive, such as in particular as a detergent additive, for decreasing or preventing deposits in the injection systems of direct-injection diesel engines, in particular in common rail injection systems, for decreasing the fuel consumption of direct-injection diesel engines, in particular of diesel engines having common rail injection systems, and for minimizing the power loss in direct-injection diesel engines, in particular in diesel engines having common rail injection systems; the invention further relates to the use as an additive for petrol, in particular for operation of DISI engines.

  该发明涉及将季铵化氮化合物用作燃料和润滑剂添加剂或煤油添加剂，特别是作为清洁剂添加剂，用于减少或预防直喷柴油发动机的喷射系统中的沉积物，在特定是在共轨喷射系统中，用于降低直喷柴油发动机的燃料消耗，特别是具有共轨喷射系统的柴油发动机，并用于减少直喷柴油发动机的功率损失，特别是在具有共轨喷射系统的柴油发动机中；该发明还涉及将其用作汽油添加剂，特别是用于DISI发动机的运行。
• TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
  申请人：Nguyen Mark Quang

  公开号：US20170129868A1

  公开（公告）日：2017-05-11

  Trientine prodrugs, pharmaceutical compositions comprising the trientine prodrugs, and methods of using trientine prodrugs and pharmaceutical compositions thereof for treating Wilson's disease.

  Trientine前药，包含Trientine前药的药物组合物，以及使用Trientine前药和药物组合物治疗威尔逊病的方法。
• Compounds that are Analogs of Squalamine, Used as Antibacterial Agents
  申请人：VIRBAC

  公开号：US20180042942A1

  公开（公告）日：2018-02-15

  The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans or animals. In formula (I), R1 and R2 are as defined in claim 1.

  这项发明涉及公式（I）的化合物，包括相同的药物组成，以及在人类或动物中用于治疗细菌、真菌、病毒和寄生虫感染或治疗癌症的用途。在公式（I）中，R1和R2如权利要求1中定义的那样。
• METHOD FOR PRODUCING TRIETHYLENETETRAMINE
  申请人：Dahmen Kirsten

  公开号：US20100029991A1

  公开（公告）日：2010-02-04

  The invention relates to a process for preparing triethylenetetramine (TETA), which comprises hydrogenating ethylenediaminediacetonitrile (EDDN) in the presence of a catalyst and a solvent.

  这项发明涉及一种制备三乙烯四胺（TETA）的过程，包括在催化剂和溶剂的存在下加氢乙二胺二乙酰腈（EDDN）。
• METHYL-SUBSTITUTED TETA COMPOUNDS
  申请人：Hugo Randolf

  公开号：US20120101303A1

  公开（公告）日：2012-04-26

  The invention relates to a process for preparing triethylenetetramine substituted by at least one methyl group (Me-TETA or methyl-substituted TETA compounds). Me-TETA is prepared by hydrogenating biscyanomethylimidazolidine (BCMI) in the presence of a catalyst. The present invention further relates to methyl-substituted TETA compounds as such. The present invention further relates to the use of methyl-substituted TETA compounds as a reactant or intermediate in the production of, for example, coatings or adhesives.

  该发明涉及一种制备至少含有一个甲基基团（Me-TETA或甲基取代的TETA化合物）的三乙烯四胺的过程。Me-TETA是通过在催化剂存在下氢化双氰甲基咪唑啉（BCMI）而制备的。本发明还涉及甲基取代的TETA化合物本身。本发明还涉及将甲基取代的TETA化合物用作反应物或中间体，例如在生产涂料或胶粘剂中的用途。